EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Moderate-to-Severe Asthma, Type 2 Inflammation, and Nocturnal Awakenings: The MORPHEO Randomized Controlled Trial

Jorge F Maspero, Anil Gupta, Olaf Schmidt, Luis A Perez de Llano, Eva Martinez Moragon, Martin Knolle, Paul E Pfeffer, Fabio Lm Ricciardolo, Simone van der Sar-van der Brugge, Cristina Lopes, Mykola Ostrovskyy, Dmytro Dobrianskyi und 6 weitere

Journal of Investigational Allergology and Clinical Immunology · 29.06.2026 · 37 (2)

DOI: 10.18176/jiaci.1160 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Investigational Allergology and Clinical Immunology, online erschienen am 29.06.2026. Verfasst von Jorge F Maspero und 17 weiteren Autor:innen. Beteiligte Einrichtung: Fundación CIDEA, Buenos Aires, Argentina.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study was performed to evaluate the effects of dupilumab on sleep disturbance in adults with uncontrolled moderateto-severe asthma in the phase 4 MORPHEO study (NCT04502862). Patients and Methods: The study population comprised adults (18-65 years) with uncontrolled (Asthma Control Questionnaire [ACQ] 5 score ≥2.5), type 2 (baseline eosinophils ≥150/μL and fractional exhaled nitric oxide [FeNO] ≥25 ppb), moderate-to-severe-asthma, and frequent nocturnal awakenings (≥1/night average). Patients were randomized 1:1 to receive dupilumab 200 mg or placebo every 2 weeks for 12 weeks. The primary endpoint was change from baseline to week 12 in the Asthma Sleep Disturbance Questionnaire (ASDQ) score. Other endpoints included changes from baseline in nocturnal awakenings, sleep quality, restorative sleep, wakefulness after sleep onset (WASO), prebronchodilator forced expiratory volume in 1 second (FEV1), ACQ-7 score, and FeNO.

Results

Of the 202 patients included, 185 (91.6%) completed the intervention. The primary endpoint was not met. Groups differed nonsignificantly at week 12 in terms of the improvement in the ASDQ score (least squares mean difference [standard error], −0.07 [0.107]; P=.512) and did not differ in terms of the decrease in the number of nocturnal awakenings (0.00 [0.110]; 95%CI, −0.21 to 0.22). Both arms improved in the secondary sleep-diary endpoints sleep quality (0.17 [0.211]; 95%CI, −0.24 to 0.59), restorative sleep (0.13 [0.212]; 95%CI, −0.29 to 0.54), and WASO (−4.10 [5.510]; 95%CI, −14.99 to 6.79) at week 12. Compared with placebo, dupilumab improved prebronchodilator FEV1, ACQ-7, and FeNO. The results were nominally statistically significant.

Conclusion

Although most sleep outcomes improved comparably in the groups, dupilumab (vs placebo) improved asthma symptoms, lung function, and airway inflammation in adults with uncontrolled, type 2, moderate-to-severe asthma and frequent nocturnal awakenings.

Schlagwörter

Stichwörter der Autor:innen

AsthmaDupilumabNocturnal awakeningsSleep disturbanceSleep quality

Autor:innen und Institutionen

  • Fundación CIDEA, Buenos Aires, Argentina.
  • All India Institute of Medical Sciences (AIIMS), New Delhi, India.
  • Lungen- und Bronchialheilkunde, Koblenz, Germany.
  • Pulmonology Service, Lucus Augusti University Hospital, EOXI Lugo, Monforte, Cervo, Lugo Spain.
  • Department of Psychiatry, Radiology, Public Health, Nursing and Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain.
  • Servicio de Neumología, Hospital Universitario Dr. Peset, Valencia, Spain.

Zitieren

APA

Maspero, J. F., Gupta, A., Schmidt, O., Perez de Llano, L. A., Martinez Moragon, E., Knolle, M., Pfeffer, P. E., Ricciardolo, F. L., van der Sar-van der Brugge, S., Lopes, C., Ostrovskyy, M., Dobrianskyi, D., Cole, J., Wachtel, A., Zhang, M., Berthou, B., Gall, R., & Awad, H. (2026). Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Moderate-to-Severe Asthma, Type 2 Inflammation, and Nocturnal Awakenings: The MORPHEO Randomized Controlled Trial. Journal of Investigational Allergology and Clinical Immunology, 37(2). https://doi.org/10.18176/jiaci.1160

Vancouver

Maspero JF, Gupta A, Schmidt O, Perez de Llano LA, Martinez Moragon E, Knolle M, et al. Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Moderate-to-Severe Asthma, Type 2 Inflammation, and Nocturnal Awakenings: The MORPHEO Randomized Controlled Trial. Journal of Investigational Allergology and Clinical Immunology. 2026;37(2). doi:10.18176/jiaci.1160

BibTeX
@article{Maspero2026,
  author = {Maspero, Jorge F and Gupta, Anil and Schmidt, Olaf and Perez de Llano, Luis A and Martinez Moragon, Eva and Knolle, Martin and Pfeffer, Paul E and Ricciardolo, Fabio Lm and van der Sar-van der Brugge, Simone and Lopes, Cristina and Ostrovskyy, Mykola and Dobrianskyi, Dmytro and Cole, Jeremy and Wachtel, Andrew and Zhang, Mei and Berthou, Baptiste and Gall, Rebecca and Awad, Hashem},
  title = {Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Moderate-to-Severe Asthma, Type 2 Inflammation, and Nocturnal Awakenings: The MORPHEO Randomized Controlled Trial},
  journal = {Journal of Investigational Allergology and Clinical Immunology},
  year = {2026},
  volume = {37},
  number = {2},
  doi = {10.18176/jiaci.1160}
}
Kostenlos starten →